DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features

EHA 2024

Multiple Myeloma (MM)

DREAMM-8: Results suggest belantamab mafodotin plus Pd as a new standard for RRMM patients with ≥1 prior line of therapy, including lenalidomide

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

EHA 2024

Multiple Myeloma (MM)

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

ESMO 2024

Gynecologic Cancer

KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

ESMO 2024

Breast Cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

ELCC 2025

Lung, Respiratory and Thoracic Cancer

Related content

DREAMM-8: Results suggest belantamab mafodotin plus Pd as a new standard for RRMM patients with ≥1 prior line of therapy, including lenalidomide

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

SAVANNAH: Savolitinib plus osimertinib shows high response rates in EGFR-mutant NSCLC with MET overexpression and/or amplification post-osimertinib

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement